Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | First real-world ctDNA analysis of oligometastic CRC

Stacey Cohen • 23 Jun 2020
ESMO WCGIC 2020
Colorectal Cancer Gastrointestinal Cancer

Stacey Cohen, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discusses the clinical experience of a personalized and tumor-informed circulating tumor DNA (ctDNA) assay for minimal residual disease (MRD) detection in oligometastatic colorectal cancer (CRC) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Stacey Cohen

0:31
Highlights in colorectal cancer at ASCO GI 2023
Stacey Cohen • 20 Jan 2023
0:59
Practical considerations for genomic testing in colorectal cancer
Stacey Cohen • 20 Jan 2023
2:17
Does postoperative cfDNA affect MRD detection rates in CRC?
Stacey Cohen • 20 Jan 2023
0:31
Applications of ctDNA in the management of colorectal cancer
Stacey Cohen • 20 Jan 2023

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals